Technology

cardiac therapeutics

cardiac therapeutics

cardiac therapeutics

cardiac therapeutics

cardiac therapeutics

SEO related. Do not remove this box.
#1

Therapy-resistant heart failure

Today, therapies prescribed for heart failure have successfully improved symptoms and survival for most patients.  
However, in a minority of patients, these evidence-based treatments do not halt the progression of the disease, which leaves them with therapy-resistant heart failure. Ironically, this most often concerns young patients with heritable forms of heart failure, including dilated cardiomyopathies.
#2

Gene therapy

We are striving to cure these cardiomyopathies by developing gene therapies that alleviate harmful protein products intracellularly. Gene therapy is a promising therapeutic platform because it targets disease-causing genes in a sequence-specific manner, which enables more precise and personalised treatment of diverse life-threatening diseases. By introducing a therapeutic specifically to the heart, gene expression can be downregulated, augmented, or corrected.
#3

PHL-001

PHL-001 is our first innovative RNA-based therapeutic product and lead candidate in the pre-clinical phase.
The technology and design of this therapeutic gene products are based on over 17 years of research and developed in the lab of Prof. Yigal M. Pinto, MD at the Amsterdam University Medical Center. Phlox focusses on the development of gene therapies that are able to induce healthy gene expression and reverse the negative effects that are caused by gene imbalance.
#4

Our pipeline

We are advancing a novel class of cardiac therapeutics with a unique mode of action for unique patients. The restorative nature of our approach at the cellular level enables us to find a cure for patients currently in palliative care. The medical need for them is as clear as day. Therefore, we will continue to develop and expand our therapeutic pipeline independently and together with partners.